Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULFAPYRIDINE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
FDA-approved for dermatitis herpetiformis,Off-label: rheumatoid arthritis, inflammatory bowel disease, and other inflammatory dermatoses
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via N-acetylation (N-acetyltransferase 2, NAT2) and glucuronidation; also undergoes hydroxylation. Excreted renally.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 50–70% bound to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd: 0.25–0.35 L/kg; clinical meaning: indicates distribution primarily into extracellular fluid, with limited tissue penetration.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 85–100% (well absorbed from gastrointestinal tract).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl 10-50 m L/min: administer every 8-12 hours. Cr Cl <10 m L/min: administer every 12-24 hours. Avoid use in severe renal impairment.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: avoid use due to potential accumulation and hepatotoxicity.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not recommended for children due to risk of kernicterus and adverse effects; safety not established.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lower end of dosing range; monitor renal function and for adverse effects; increased risk of sulfonamide-induced reactions.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Severe hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), hematologic toxicity (agranulocytosis, hemolytic anemia in G6PD deficiency), hepatotoxicity, renal toxicity. Discontinue if rash or signs of hypersensitivity.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to sulfonamides, porphyria, severe hepatic or renal impairment, pregnancy (especially near term) and lactation, infants <2 months (except for congenital toxoplasmosis).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. Avoid alcohol as it may increase risk of adverse effects like disulfiram-like reaction. Ensure adequate hydration with water; acidic foods do not significantly affect absorption.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Sulfapyridine, a sulfonamide, crosses the placenta. There is a potential risk of neural tube defects and other malformations based on animal studies, but human data are limited. Second and third trimesters: Sulfonamides compete with bilirubin for albumin binding, increasing the risk of kernicterus in the neonate if administered near term. Use is generally avoided after 32 weeks gestation.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Sulfapyridine is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.45. Low levels are unlikely to cause adverse effects in healthy term infants, but caution is advised in premature, ill, or G6PD-deficient infants due to potential for hemolysis or kernicterus.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustments are recommended, but pharmacokinetic changes in pregnancy (increased volume of distribution and renal clearance) may reduce drug levels. Monitor therapeutic response and consider adjusting dose based on clinical indication and serum levels if available.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Sulfapyridine is primarily used for dermatitis herpetiformis (DH). Dose adjustments needed in renal impairment. Monitor for hypersensitivity reactions, hemolytic anemia in G6PD deficiency, and crystalluria. Increase fluid intake to 2-3 L/day to prevent renal toxicity. Not first-line for other infections due to resistance.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with a full glass of water and maintain high fluid intake to prevent kidney stones.,Avoid prolonged sun exposure and use sunscreen, as sulfonamides can cause photosensitivity.,Report any skin rash, fever, sore throat, or unusual bleeding immediately.,Complete full course as prescribed, but do not use for viral infections.,Inform doctor if pregnant, breastfeeding, or have glucose-6-phosphate dehydrogenase deficiency.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULFAPYRIDINE vs ABSTRAL, answered by our medical review team.
SULFAPYRIDINE is a Sulfonamide Antibiotic that works by Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULFAPYRIDINE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULFAPYRIDINE is: 500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULFAPYRIDINE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULFAPYRIDINE is classified as Category C. First trimester: Sulfapyridine, a sulfonamide, crosses the placenta. There is a potential risk of neural tube defects and other malformations based on animal studies, but human dat. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.